Human cytomegalovirus (CMV) is the major infectious cause of birth defects in the United States. Each year transmission of CMV from mother-to-fetus during pregnancy results in the birth of ~40,000 CMV-infected babies. While most suffer no overt ill effects from infection, ~8000 exhibit severe complications at birth and ~400 die within the first week of life. Of those that appear normal at birth another ~8000 may develop progressive and permanent hearing loss later in childhood. Both live attenuated and subunit CMV vaccines are under development. In both cases neutralizing antibodies to glycoprotein B (gB) have been emphasized as this protein is a key player in viral attachment and entry. However, past studies have measured the ability of antisera to block entry of CMV into fibroblast cells. Very recently it has been discovered that CMV can enter and infect endothelial, epithelial, and dendritic cells by an """"""""endocytic"""""""" pathway that is quite distinct from the pathway used to infect fibroblasts. This pathway may be far more relevant in vivo than fibroblast entry. We hypothesize that viral entry into epithelial and endothelial cells may be blocked by antibodies specifically targeting viral proteins that mediate endocytic entry. Moreover, existing live attenuated vaccine strategies may lack efficacy because they fail to induce neutralizing antibodies specific for these endocytic-entry epitopes. Our objective is to promote development of an effective vaccine to prevent CMV-associated birth defects by (1) determining the extent to which neutralizing antibodies specifically targeting endocytic entry are induced by vaccination and natural infection;and (2) cloning the Townelong virus, which comprises a major component of the live attenuated Towne vaccine, defining its genetic composition, and characterizing the genetic and mechanistic basis of its cellular tropisms. The results of the proposed studies will guide the design of new vaccines or suggest modifications to existing vaccine strategies that have the potential to significantly improve vaccine efficacy. Project Narrative: Human cytomegalovirus (CMV) is the major infectious cause of birth defects in the United States. To promote development of an effective CMV vaccine, we propose to evaluate the importance of antibodies to recently identified proteins that are specifically involved in CMV entry into endothelial and epithelial cells and to determine the extent to which existing candidate vaccines are able to induce such antibodies and block epithelial/endothelial cell entry. The results of the proposed studies may reveal important shortcomings that could be addressed in the design of new vaccines or suggest modifications to existing vaccine strategies that will improve induction of antibodies targeting this entry pathway.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI073615-02
Application #
7670404
Study Section
Vaccines Against Microbial Diseases (VMD)
Program Officer
Beisel, Christopher E
Project Start
2008-08-15
Project End
2011-07-31
Budget Start
2009-08-01
Budget End
2011-07-31
Support Year
2
Fiscal Year
2009
Total Cost
$182,133
Indirect Cost
Name
Virginia Commonwealth University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Cui, Xiaohong; Freed, Daniel C; Wang, Dai et al. (2017) Impact of Antibodies and Strain Polymorphisms on Cytomegalovirus Entry and Spread in Fibroblasts and Epithelial Cells. J Virol 91:
Cui, Xiaohong; Adler, Stuart P; Schleiss, Mark R et al. (2017) Cytomegalovirus Virions Shed in Urine Have a Reversible Block to Epithelial Cell Entry and Are Highly Resistant to Antibody Neutralization. Clin Vaccine Immunol 24:
Alam, Zohaib; Al-Mahdi, Zainab; Zhu, Yali et al. (2015) Anti-cytomegalovirus activity of the anthraquinone atanyl blue PRL. Antiviral Res 114:86-95
Kauvar, Lawrence M; Liu, Keyi; Park, Minha et al. (2015) A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types. Antimicrob Agents Chemother 59:1558-68
McVoy, Michael A; Lee, Ronzo; Saccoccio, Frances M et al. (2015) A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells. Vaccine 33:7328-7336
Cui, Xiaohong; Lee, Ronzo; Adler, Stuart P et al. (2013) Antibody inhibition of human cytomegalovirus spread in epithelial cell cultures. J Virol Methods 192:44-50
Bhave, Sukhada; Elford, Howard; McVoy, Michael A (2013) Ribonucleotide reductase inhibitors hydroxyurea, didox, and trimidox inhibit human cytomegalovirus replication in vitro and synergize with ganciclovir. Antiviral Res 100:151-8
Cui, Xiaohong; Adler, Stuart P; Davison, Andrew J et al. (2012) Bacterial artificial chromosome clones of viruses comprising the towne cytomegalovirus vaccine. J Biomed Biotechnol 2012:428498
Saccoccio, Frances M; Sauer, Anne L; Cui, Xiaohong et al. (2011) Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells. Vaccine 29:2705-11
Cui, Xiaohong; Meza, Benjamin P; Adler, Stuart P et al. (2008) Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26:5760-6